Polypharmacy in Older Adults With Hypertension: A Comprehensive Review

Journal of Clinical Hypertension

Volumn 18, Issue 1, 2016, Pages 10-18

  Mukete, Bertrand N ^a   Ferdinand, Keith C ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS ATORVASTATIN PLUS RAMIPRIL; ACETYLSALICYLIC ACID PLUS SIMVASTATIN PLUS RAMIPRIL; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; ERGOTAMINE; GLUCOCORTICOID; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POLYPILL; RECOMBINANT ERYTHROPOIETIN; SEX HORMONE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; ELECTRONIC REMINDER SYSTEM; ESTROGEN THERAPY; FALLING; GENERAL DEVICE; GRAPEFRUIT JUICE; HEALTH CARE COST; HUMAN; HYPERTENSION; INGESTIBLE SENSOR SYSTEM; LONG TERM CARE; MEDICAL AUDIT; MEDICAL TECHNOLOGY; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; RISK FACTOR; SENSOR; SYSTOLIC BLOOD PRESSURE; TREATMENT REFUSAL; AGED; BLOOD PRESSURE; DRUG INTERACTION; FEMALE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYPHARMACY;

EID: 84953637675     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12624     Document Type: Article

References (86)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
3. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013;133:1-8.
4. Administration on Aging. Aging Statistics: Projected Future Growth of Older Population. Available from: http://www.aoa.gov/AoARoot/Aging_Statistics/index.aspx. Accessed November 12, 2013.
5. Werner CA. 2010 Census Brief. The Older Population: 2010: http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed November 12, 2013.
6. Black HR, Elliott WJ. Hypertension: A Companion to Braunwald's Heart Disease. Hypertension in Older Patients, 2nd ed. Philadelphia, PA: Saunders-Elsevier; 2013: 349-355.
7. Grebla RC, Rodriguez CJ, Borrell LN, Pickering TG. Prevalence and determinants of isolated systolic hypertension among young adults: the 1999-2004 US National Health And Nutrition Examination Survey. J Hypertens. 2010;28:15-23.
8. Golchin N, Frank SH, Vince A, et al. Polypharmacy in the elderly. J Res Pharm Prac. 2015;4:85-88.
9. IMS institute for healthcare informatics. Nurs Standard. 2014;28:30.
10. Avoidable Costs in U.S. Healthcare. IMS Institute for Healthcare Informatics; June 2013.
11. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64:2071-2082.
12. Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014;64:613-21.
13. Egan BM, Li J, Shatat IF, et al. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014;129:2052-2061.
14. Bitton A, Choudhry NK, Matlin OS, et al. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126:357e7-357e27.
15. Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect. 2005;113:1243-1249.
16. Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med. 2009;25:221-233.
17. Sleight P. Smoking and hypertension. Clin Exp Hypertens. 1993;15:1181-1192.
18. Halimi JM, Giraudeau B, Vol S, et al. The risk of hypertension in men: direct and indirect effects of chronic smoking. J Hypertens. 2002;20:187-193.
19. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037-2114.
20. Mesas AE, Leon-Munoz LM, Rodriguez-Artalejo F, Lopez-Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr. 2011;94:1113-1126.
21. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624.
22. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. J Am Med Assoc 1994;272:781-786.
23. Schnitzer TJ. Cyclooxygenase-2-specific inhibitors: are they safe? Am J Med. 2001;110:46S-49S.
24. MacDonald TM, Richard D, Lheritier K, Krammer G. The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. Int J Clin Pract. 2010;64:746-755.
25. Ishiguro C, Fujita T, Omori T, et al. Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database. J Epidemiol. 2008;18:119-124.
26. Stollberger C, Finsterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J. 2004;97:209.
27. Johnson AG, Nguyen TV, Owe-Young R, et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens. 1996;10:257-261.
28. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15:e372-e382.
29. Gualtierotti R, Zoppi A, Mugellini A, et al. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. Expert Opin Pharmacother. 2013;14:1875-1884.
30. Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. Br J Clin Pharmacol. 2013;75:1396-1405.
31. Dawson J, Fulton R, McInnes GT, et al. Acetaminophen use and change in blood pressure in a hypertensive population. J Hypertens. 2013;31:1485-1490; discussion 1490.
32. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
33. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
34. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther. 2006;79:9-19.
35. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002;99:13926-13931.
36. Sudano I, Flammer AJ, Periat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122:1789-1796.
37. Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London; 2011.
38. Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep. 2004;6:493-499.
39. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27:1059-1066.
40. Izzo JL, Sica DA, Black HR, Council for High Blood Pressure Research (American Heart Association). Hypertension Primer: [The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management], 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
41. Steiner AZ, Hodis HN, Lobo RA, et al. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. Menopause. 2005;12:728-733.
42. Ioka T, Tsuruoka S, Ito C, et al. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients. Clin Pharmacol Ther. 2009;86:154-159.
43. Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol. 1991;261(5 Pt 1):E642-E646.
44. Hand MF, Haynes WG, Johnstone HA, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int. 1995;48:806-813.
45. Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993;43:1010-1014.
46. Morakkabati N, Gollnick F, Meyer R, et al. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol. 1996;24:392-397.
47. Schulz EG, Neumann CL, Menne J, et al. An erythropoietin gene polymorphism in the hypoxia-responsive element at position 3434 is possibly associated with hypertension. Kidney Blood Press Res. 2012;35:71-76.
48. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123 (Pt 1): 9-18.
49. Tfelt-Hansen P, Ostergaard JR, Gothgen I, et al. Nitroglycerin for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case. Eur J Clin Pharmacol. 1982;22:105-109.
50. Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia. 1997;17:639-646.
51. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46:101-110.
52. Bailey DG, Kreeft JH, Munoz C, et al. Grapefruit juice-felodipine interaction: effect of naringin and 6′, 7′-dihydroxybergamottin in humans. Clin Pharmacol Ther. 1998;64:248-256.
53. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337:268-269.
54. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Sys Rev 2009;(4):CD000028.
55. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588-595.
56. Group AS, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
57. Group SPSS, Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15.
58. Pickering G. High Blood Pressure, 2nd ed. London, UK: J&A Churchill Ltd; 1968.
59. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J. 1985;291:97-104.
60. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. J Am Med Assoc. 1982;247:633-638.
61. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
62. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.
63. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;31:2837-2840.
64. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the argument. Hypertension. 2014;63:29-36.
65. Sundstrom J, Sheikhi R, Ostgren CJ, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J Hypertens. 2013;31:1603-1610.
66. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc. 2014;311:507-520.
67. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc. 2003;289:2560-2572.
68. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
69. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. J Am Med Assoc. 1991;265:3255-3264.
70. Group JS. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-2127.
71. Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196-202.
72. Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. Am J Cardiovasc Drugs. 2013;13:301-313.
73. Wright JT Jr, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503.
74. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
75. Langer RD, Criqui MH, Barrett-Connor EL, et al. Blood pressure change and survival after age 75. Hypertension. 1993;22:551-559.
76. Rastas S, Pirttila T, Viramo P, et al. Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc. 2006;54:912-918.
77. van Bemmel T, Woittiez K, Blauw GJ, et al. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. J Am Soc Nephrol. 2006;17:2561-2566.
78. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376, 162 patients. Am J Med. 2012;125:882e1-882e7.
79. 79 PS, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Sys Rev 2014;10:CD008165.
80. Sanz G, Fuster V, Guzman L, et al. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J. 2011;162:811-817 e1.
81. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
82. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
83. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. Am J Med. 2009;122:290-300.
84. Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: a review of the evidence. Am J Health Syst Pharm. 2010;67:885-894.
85. Eisenberger U, Wuthrich RP, Bock A, et al. Medication adherence assessment: high accuracy of the new Ingestible Sensor System in kidney transplants. Transplantation. 2013;96:245-250.
86. Werder SF, Preskorn SH. Managing polypharmacy: walking a fine line between help and harm. Curr Psychiatry Online. 2003;2:24-36.